
Atossa Therapeutics Closes $4.5 Million Registered Direct Offering
Seattle-based clinical-stage biopharmaceutical firm Atossa Therapeutics has finalized a registered direct offering, securing $4.5 million in upfront gross proceeds. The deal, facilitated by Rodman & Renshaw LLC, includes common stock and warrants that could generate an additional $12 million should they be fully exercised in the future.








/bmi/media/post_banners/685374a708a95156958d6658a6e64c51d2d6e73262d48b69d1988c2ac58cb616.jpg)

















